Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, Elizabeth A, Vora, Sheetal S, Verbsky, James W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511797/
https://www.ncbi.nlm.nih.gov/pubmed/22931129
http://dx.doi.org/10.1186/1546-0096-10-30
_version_ 1782251651679125504
author Kessler, Elizabeth A
Vora, Sheetal S
Verbsky, James W
author_facet Kessler, Elizabeth A
Vora, Sheetal S
Verbsky, James W
author_sort Kessler, Elizabeth A
collection PubMed
description Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab.
format Online
Article
Text
id pubmed-3511797
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35117972012-12-02 Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome Kessler, Elizabeth A Vora, Sheetal S Verbsky, James W Pediatr Rheumatol Online J Case Report Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab. BioMed Central 2012-08-29 /pmc/articles/PMC3511797/ /pubmed/22931129 http://dx.doi.org/10.1186/1546-0096-10-30 Text en Copyright ©2012 Kessler et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kessler, Elizabeth A
Vora, Sheetal S
Verbsky, James W
Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
title Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
title_full Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
title_fullStr Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
title_full_unstemmed Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
title_short Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
title_sort risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511797/
https://www.ncbi.nlm.nih.gov/pubmed/22931129
http://dx.doi.org/10.1186/1546-0096-10-30
work_keys_str_mv AT kesslerelizabetha riskofsignificantcytopeniasaftertreatmentwithtocilizumabinsystemicjuvenilearthritispatientswithahistoryofmacrophageactivationsyndrome
AT vorasheetals riskofsignificantcytopeniasaftertreatmentwithtocilizumabinsystemicjuvenilearthritispatientswithahistoryofmacrophageactivationsyndrome
AT verbskyjamesw riskofsignificantcytopeniasaftertreatmentwithtocilizumabinsystemicjuvenilearthritispatientswithahistoryofmacrophageactivationsyndrome

Ejemplares similares